A Phase II Trial of Exploring the Predictive Factors of TX and XELOX Regimen in the First Line Treatment of MGC
Status:
Unknown status
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
Platinum, fluorouracil and taxane based regimen are all acceptable in the first line
treatment of metastatic gastric cancer. The TX and XELOX regimen are two common regimen used
in MGC. whichever regimen is used, the average response rate is less than 50%. So a rather
part of patients can't get benefit from the treatment. It is urgent to find out the
predictive factors of these regimens in order to get a higher response and better survival
outcome.